CIITA
Summary: This gene encodes a protein with an acidic transcriptional activation domain, 4 LRRs (leucine-rich repeats) and a GTP binding domain. The protein is located in the nucleus and acts as a positive regulator of class II major histocompatibility complex gene transcription, and is referred to as the 'master control factor' for the expression of these genes. The protein also binds GTP and uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus it does not bind DNA but rather uses an intrinsic acetyltransferase (AT) activity to act in a coactivator-like fashion. Mutations in this gene have been associated with bare lymphocyte syndrome type II (also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency), increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardial infarction. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2013].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| class II major histocompatibility complex transactivator | MIM:600005 | Ensembl:ENSG00000179583 | HGNC:HGNC:7067 | PA30795 | 16p13.13 |
GO terms in CIITA
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| BP | IMP | GO:0000122 | negative regulation of transcription by RNA polymerase II |
| BP | IEA | GO:0006351 | transcription, DNA-templated |
| BP | TAS | GO:0006955 | immune response |
| BP | IEA | GO:0016310 | phosphorylation |
| BP | IC | GO:0032966 | negative regulation of collagen biosynthetic process |
| BP | IDA | GO:0034341 | response to interferon-gamma |
| BP | IDA | GO:0045345 | positive regulation of MHC class I biosynthetic process |
| BP | IC | GO:0045348 | positive regulation of MHC class II biosynthetic process |
| BP | IDA | GO:0045892 | negative regulation of transcription, DNA-templated |
| BP | IDA | GO:0045893 | positive regulation of transcription, DNA-templated |
| BP | IBA | GO:0045944 | positive regulation of transcription by RNA polymerase II |
| BP | IDA | GO:0045944 | positive regulation of transcription by RNA polymerase II |
| BP | IMP | GO:0045944 | positive regulation of transcription by RNA polymerase II |
| BP | IDA | GO:0046677 | response to antibiotic |
| BP | TAS | GO:0060333 | interferon-gamma-mediated signaling pathway |
| CC | TAS | GO:0005654 | nucleoplasm |
| CC | IDA | GO:0016605 | PML body |
| MF | TAS | GO:0003677 | DNA binding |
| MF | TAS | GO:0003713 | transcription coactivator activity |
| MF | IPI | GO:0005515 | protein binding |
| MF | IEA | GO:0005524 | ATP binding |
| MF | IEA | GO:0005525 | GTP binding |
| MF | IPI | GO:0008022 | protein C-terminus binding |
| MF | IEA | GO:0016301 | kinase activity |
| MF | IEA | GO:0016746 | transferase activity, transferring acyl groups |
| MF | IPI | GO:0033613 | activating transcription factor binding |
| MF | IDA | GO:0044212 | transcription regulatory region DNA binding |
| MF | IDA | GO:0044877 | protein-containing complex binding |
Gene expression in normal tissue: CIITA
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in CIITA
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| wikipathways | WP619 | Type II interferon signaling (IFNG) |
| kegg | hsa04612 | Antigen processing and presentation - Homo sapiens (human) |
| kegg | hsa05145 | Toxoplasmosis - Homo sapiens (human) |
| kegg | hsa05152 | Tuberculosis - Homo sapiens (human) |
| kegg | hsa05164 | Influenza A - Homo sapiens (human) |
| kegg | hsa05340 | Primary immunodeficiency - Homo sapiens (human) |
| reactome | R-HSA-1280215 | Cytokine Signaling in Immune system |
| reactome | R-HSA-168256 | Immune System |
| reactome | R-HSA-877300 | Interferon gamma signaling |
| reactome | R-HSA-913531 | Interferon Signaling |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD781 | Sirolimus | 4 |
| iGMDRD546 | BMS-754807 | 6 |
| iGMDRD427 | ABT737 | 2 |
| iGMDRD670 | ML 210 | 3 |
| iGMDRD1008 | SR-II-138A | 3 |
| iGMDRD772 | BRD4770 | 3 |
| iGMDRD375 | GW-405833 | 3 |
| iGMDRD280 | CYTOCHALASIN B | 5 |
| iGMDRD466 | Chaetocin | 2 |
| iGMDRD187 | BRD9876 | 1 |
| iGMDRD294 | Batimastat | 2 |
| iGMDRD226 | ML006 | 3 |
| iGMDRD885 | Compound 110 | 3 |
| iGMDRD318 | PAC-1 | 6 |
| iGMDRD801 | 2,4-dideoxy-DC-45-A2 | 2 |
| iGMDRD802 | 4-methylfasudil | 2 |
| iGMDRD451 | Serdemetan | 4 |
| iGMDRD524 | ISX-9 | 3 |
| iGMDRD60 | Quinoclamine | 3 |
| iGMDRD369 | TGX-115 | 2 |
| iGMDRD690 | PRIMA-1MET | 3 |
| iGMDRD780 | PP-30 | 3 |
| iGMDRD562 | Navitoclax | 6 |
| iGMDRD506 | Fedratinib | 3 |
| iGMDRD730 | Kahalalide F | 3 |
| iGMDRD887 | Compound 23 citrate | 2 |
| iGMDRD74 | Idarubicin | 3 |
| iGMDRD399 | Selumetinib | 4 |
| iGMDRD405 | PIK-75 | 2 |
| iGMDRD523 | Cyanoquinoline, 11 | 3 |
| iGMDRD560 | MK-2206 | 1 |
| iGMDRD512 | nutlin 3 | 3 |
| iGMDRD132 | (-)-gallocatechin-3-O-gallate | 3 |
| iGMDRD945 | ML214 | 2 |
| iGMDRD154 | NSC23766 | 4 |
| iGMDRD211 | (1S,3R)-RSL3 | 3 |
| iGMDRD57 | Chloropentafluorobenzene | 2 |
| iGMDRD314 | Tanespimycin | 3 |
| iGMDRD461 | VX-11e | 1 |
| iGMDRD341 | Triacsin c | 1 |
| iGMDRD376 | Tivozanib | 1 |
| iGMDRD267 | Oligomycin A | 3 |
| iGMDRD481 | Dactolisib | 3 |
| iGMDRD434 | BMS-536924 | 6 |
| iGMDRD289 | Parthenolide | 1 |
| iGMDRD221 | Tamoxifen | 1 |
| iGMDRD158 | NSC141540 | 4 |
| iGMDRD137 | Indisulam | 2 |
| iGMDRD179 | Shikonin | 1 |
| iGMDRD300 | Tozasertib | 3 |
| iGMDRD366 | PI-103 | 1 |
| iGMDRD329 | Merck60 | 9 |
| iGMDRD872 | BRD7137 | 6 |
| iGMDRD414 | MST-312 | 3 |
| iGMDRD871 | BRD6368 | 6 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in CIITA
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.